Research programme: selective alpha-1A adrenoceptor antagonists - Lundbeck

Drug Profile

Research programme: selective alpha-1A adrenoceptor antagonists - Lundbeck

Alternative Names: Alpha 1A adrenoceptor antagonists research programme - Lundbeck

Latest Information Update: 31 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck Research USA
  • Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Lundbeck Research USA; Sun Pharmaceutical Industries
  • Class
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
  • 06 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
  • 11 Jul 2002 Synpatic's alpha1A receptor antagonists have been licensed to Ranbaxy in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top